Title:
INTERLEUKIN-12 TARGETED TO ONCOFOETAL FIBRONECTIN
Document Type and Number:
WIPO Patent Application WO2005066348
Kind Code:
A3
Abstract:
The invention provides a compound comprising a target specific portion and an effector portion wherein the target specific portion comprises or consists of a monoclonal antibody having specificity for oncofoetal fibronectin, or a fragment or variant thereof which retains the antigen binding specificity of the parent monoclonal antibody and the effector portion comprises or consists of interleukin-12, or a functional fragment or variant thereof, characterised in the monoclonal antibody having specificity for oncofoetal fibronectin binds to a region of oncofoetal fibronectin other than the ED-B region. The invention further provides nucleic acids encoding the compounds of the invention, and the use of such compounds in medicine, e.g. in the treatment of cancer.
Inventors:
GILLIES STEPHEN (US)
LO KIN-MING (US)
LAN YAN (US)
VERMA RAKESH (GB)
LO KIN-MING (US)
LAN YAN (US)
VERMA RAKESH (GB)
Application Number:
PCT/GB2005/000007
Publication Date:
November 10, 2005
Filing Date:
January 05, 2005
Export Citation:
Assignee:
EMD LEXIGEN RES CT CORP (US)
ANTISOMA PLC (GB)
GILLIES STEPHEN (US)
LO KIN-MING (US)
LAN YAN (US)
VERMA RAKESH (GB)
ANTISOMA PLC (GB)
GILLIES STEPHEN (US)
LO KIN-MING (US)
LAN YAN (US)
VERMA RAKESH (GB)
International Classes:
A61K47/48; C07K14/54; C07K16/24; C07K16/30; C12N15/62; (IPC1-7): C12N15/62; A61K47/48; C07K14/54; C07K16/30; A61P35/00
Domestic Patent References:
| WO2003093478A1 | 2003-11-13 | |||
| WO1999029732A2 | 1999-06-17 | |||
| WO2002002143A2 | 2002-01-10 |
Other References:
HALIN CORNELIA ET AL: "Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.", CANCER RESEARCH, vol. 63, no. 12, 15 June 2003 (2003-06-15), pages 3202 - 3210, XP002342601, ISSN: 0008-5472
THORPE P E ET AL: "The First International Conference on Vascular Targeting: Meeting overview", CANCER RESEARCH 01 MAR 2003 UNITED STATES, vol. 63, no. 5, 1 March 2003 (2003-03-01), pages 1144 - 1147, XP002342602, ISSN: 0008-5472
HALIN C ET AL: "Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 20, no. 3, March 2002 (2002-03-01), pages 264 - 269, XP002256784, ISSN: 1087-0156
HUANG X ET AL: "TUMOR INFARCTION IN MICE BY ANTIBODY-DIRECTED TARGETING OF TISSUE FACTOR TO TUMOR VASCULATURE", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 275, 24 January 1997 (1997-01-24), pages 547 - 550, XP002071588, ISSN: 0036-8075
VAN VLIET A I ET AL: "Distribution of fibronectin isoforms in human renal disease", JOURNAL OF PATHOLOGY 2001 UNITED KINGDOM, vol. 193, no. 2, 2001, pages 256 - 262, XP002342603, ISSN: 0022-3417
VITI F ET AL: "Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis", CANCER RESEARCH 15 JAN 1999 UNITED STATES, vol. 59, no. 2, 15 January 1999 (1999-01-15), pages 347 - 352, XP002124782, ISSN: 0008-5472
CARNEMOLLA B ET AL: "A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors", JOURNAL OF CELL BIOLOGY 1989 UNITED STATES, vol. 108, no. 3, 1989, pages 1139 - 1148, XP002342604, ISSN: 0021-9525
ZHU Z ET AL: "INHIBITION OF TUMOR GROWTH AND METASTASIS BY TARGETING TUMOR-ASSOCIATED ANGIOGENESIS WITH ANTAGONISTS TO THE RECEPTORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR", INVESTIGATIONAL NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US, vol. 17, no. 3, 1999, pages 195 - 212, XP000940444, ISSN: 0167-6997
PENG L S ET AL: "Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3)", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. 21, no. 9, 2001, pages 709 - 720, XP002342605, ISSN: 1079-9907
LADELL KRISTIN ET AL: "A combination of plasmid DNAs encoding murine fetal liver kinase 1 extracellular domain, murine interleukin-12, and murine interferon-gamma inducible protein-10 leads to tumor regression and survival in melanoma-bearing mice.", JOURNAL OF MOLECULAR MEDICINE (BERLIN), vol. 81, no. 4, April 2003 (2003-04-01), pages 271 - 278, XP002342606, ISSN: 0946-2716
DICKERSON ERIN B ET AL: "Development of an IL-12 fusion protein for molecular targeting of tumor vasculature", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 41, March 2000 (2000-03-01), & 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.; SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000, pages 798, ABSTRACT NO. 5074, XP002342607, ISSN: 0197-016X
MAJEWSKI S ET AL: "INTERLEUKIN-12 INHIBITS ANGIOGENESIS INDUCED BY HUMAN TUMOR CELL LINES IN VIVO", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NEW YORK, NY, US, vol. 106, no. 5, 1996, pages 1114 - 1118, XP000949299, ISSN: 0022-202X
THORPE P E ET AL: "The First International Conference on Vascular Targeting: Meeting overview", CANCER RESEARCH 01 MAR 2003 UNITED STATES, vol. 63, no. 5, 1 March 2003 (2003-03-01), pages 1144 - 1147, XP002342602, ISSN: 0008-5472
HALIN C ET AL: "Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 20, no. 3, March 2002 (2002-03-01), pages 264 - 269, XP002256784, ISSN: 1087-0156
HUANG X ET AL: "TUMOR INFARCTION IN MICE BY ANTIBODY-DIRECTED TARGETING OF TISSUE FACTOR TO TUMOR VASCULATURE", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 275, 24 January 1997 (1997-01-24), pages 547 - 550, XP002071588, ISSN: 0036-8075
VAN VLIET A I ET AL: "Distribution of fibronectin isoforms in human renal disease", JOURNAL OF PATHOLOGY 2001 UNITED KINGDOM, vol. 193, no. 2, 2001, pages 256 - 262, XP002342603, ISSN: 0022-3417
VITI F ET AL: "Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis", CANCER RESEARCH 15 JAN 1999 UNITED STATES, vol. 59, no. 2, 15 January 1999 (1999-01-15), pages 347 - 352, XP002124782, ISSN: 0008-5472
CARNEMOLLA B ET AL: "A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors", JOURNAL OF CELL BIOLOGY 1989 UNITED STATES, vol. 108, no. 3, 1989, pages 1139 - 1148, XP002342604, ISSN: 0021-9525
ZHU Z ET AL: "INHIBITION OF TUMOR GROWTH AND METASTASIS BY TARGETING TUMOR-ASSOCIATED ANGIOGENESIS WITH ANTAGONISTS TO THE RECEPTORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR", INVESTIGATIONAL NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US, vol. 17, no. 3, 1999, pages 195 - 212, XP000940444, ISSN: 0167-6997
PENG L S ET AL: "Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3)", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. 21, no. 9, 2001, pages 709 - 720, XP002342605, ISSN: 1079-9907
LADELL KRISTIN ET AL: "A combination of plasmid DNAs encoding murine fetal liver kinase 1 extracellular domain, murine interleukin-12, and murine interferon-gamma inducible protein-10 leads to tumor regression and survival in melanoma-bearing mice.", JOURNAL OF MOLECULAR MEDICINE (BERLIN), vol. 81, no. 4, April 2003 (2003-04-01), pages 271 - 278, XP002342606, ISSN: 0946-2716
DICKERSON ERIN B ET AL: "Development of an IL-12 fusion protein for molecular targeting of tumor vasculature", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 41, March 2000 (2000-03-01), & 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.; SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000, pages 798, ABSTRACT NO. 5074, XP002342607, ISSN: 0197-016X
MAJEWSKI S ET AL: "INTERLEUKIN-12 INHIBITS ANGIOGENESIS INDUCED BY HUMAN TUMOR CELL LINES IN VIVO", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NEW YORK, NY, US, vol. 106, no. 5, 1996, pages 1114 - 1118, XP000949299, ISSN: 0022-202X
Download PDF: